Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-10-19

Clinical Trial Update: Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating efficacy and safety of osilodrostat in Cushing's disease has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Osilodrostat (osilodrostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing's Disease | Phase 3 | Status: COMPLETED | Results posted: 2021-10-19